1,401 Shares in Cencora, Inc. (NYSE:COR) Acquired by Fermata Advisors LLC

Fermata Advisors LLC purchased a new stake in Cencora, Inc. (NYSE:COR) in the 4th quarter, Holdings Channel.com reports. The fund purchased 1,401 shares of the company’s stock, valued at approximately $315,000.

Other large investors also recently made changes to their positions in the company. Lake Street Advisors Group LLC boosted its position in shares of Cencora by 1.3% in the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock worth $769,000 after acquiring an additional 43 shares during the last quarter. Venturi Wealth Management LLC raised its stake in Cencora by 1.0% during the third quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock worth $1,001,000 after purchasing an additional 46 shares during the period. Prime Capital Investment Advisors LLC raised its stake in Cencora by 1.2% during the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock worth $848,000 after purchasing an additional 46 shares during the period. J.W. Cole Advisors Inc. boosted its holdings in shares of Cencora by 1.3% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company’s stock valued at $826,000 after purchasing an additional 48 shares during the last quarter. Finally, Impact Partnership Wealth LLC grew its stake in shares of Cencora by 2.6% during the 3rd quarter. Impact Partnership Wealth LLC now owns 2,042 shares of the company’s stock valued at $460,000 after buying an additional 51 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.5 %

NYSE COR opened at $242.11 on Friday. The stock has a market cap of $46.80 billion, a P/E ratio of 32.24, a PEG ratio of 1.48 and a beta of 0.49. The company’s fifty day simple moving average is $237.52 and its 200-day simple moving average is $233.85. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $253.27.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a $0.55 dividend. The ex-dividend date was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is currently 29.29%.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares in the company, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 94,696 shares of company stock valued at $22,862,734 in the last ninety days. Insiders own 15.80% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the topic of several research reports. Robert W. Baird increased their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Evercore ISI lifted their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Wells Fargo & Company decreased their target price on Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a report on Friday, December 13th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Finally, Leerink Partners decreased their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $275.60.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.